ATE526325T1 - Substituierte benzimidazole als kinaseinhibitoren - Google Patents

Substituierte benzimidazole als kinaseinhibitoren

Info

Publication number
ATE526325T1
ATE526325T1 AT06824870T AT06824870T ATE526325T1 AT E526325 T1 ATE526325 T1 AT E526325T1 AT 06824870 T AT06824870 T AT 06824870T AT 06824870 T AT06824870 T AT 06824870T AT E526325 T1 ATE526325 T1 AT E526325T1
Authority
AT
Austria
Prior art keywords
kinase inhibitors
substituted benzimidazoles
benzimidazoles
substituted
kinase
Prior art date
Application number
AT06824870T
Other languages
English (en)
Inventor
Mina E Aikawa
Payman Amiri
Jeffrey H Dove
Barry Haskell Levine
Christopher Mcbride
Teresa E Pick
Daniel J Poon
Savithri Ramurthy
Paul A Renhowe
Cynthia Shafer
Darrin Stuart
Sharadha Subramanian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE526325T1 publication Critical patent/ATE526325T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT06824870T 2005-08-30 2006-08-30 Substituierte benzimidazole als kinaseinhibitoren ATE526325T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US71310805P 2005-08-30 2005-08-30
US71253905P 2005-08-30 2005-08-30
US73159105P 2005-10-27 2005-10-27
US77468406P 2006-02-17 2006-02-17
PCT/US2006/034088 WO2007030377A1 (en) 2005-08-30 2006-08-30 Substituted benzimidazoles as kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE526325T1 true ATE526325T1 (de) 2011-10-15

Family

ID=37434025

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06824870T ATE526325T1 (de) 2005-08-30 2006-08-30 Substituierte benzimidazole als kinaseinhibitoren
AT06790127T ATE503751T1 (de) 2005-08-30 2006-08-30 Substituierte benzimidazole und herstellungsverfahren dafür

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06790127T ATE503751T1 (de) 2005-08-30 2006-08-30 Substituierte benzimidazole und herstellungsverfahren dafür

Country Status (37)

Country Link
US (6) US20070049622A1 (de)
EP (2) EP1924577B1 (de)
JP (4) JP5210867B2 (de)
KR (2) KR20080039965A (de)
AR (2) AR055622A1 (de)
AT (2) ATE526325T1 (de)
AU (2) AU2006284666B2 (de)
BR (2) BRPI0615314A2 (de)
CA (2) CA2619966A1 (de)
CR (1) CR9716A (de)
CU (1) CU23784B7 (de)
CY (2) CY1111871T1 (de)
DE (1) DE602006021036D1 (de)
DK (2) DK1924577T3 (de)
EA (1) EA014230B1 (de)
EC (2) ECSP088210A (de)
ES (1) ES2374451T3 (de)
GE (1) GEP20105004B (de)
GT (1) GT200600394A (de)
HK (2) HK1117519A1 (de)
HN (1) HN2008000317A (de)
HR (2) HRP20110312T1 (de)
IL (2) IL189080A (de)
MA (2) MA29772B1 (de)
MY (2) MY163886A (de)
NI (1) NI200800060A (de)
NO (1) NO20081476L (de)
NZ (2) NZ565450A (de)
PE (2) PE20070427A1 (de)
PL (2) PL1926722T3 (de)
PT (2) PT1926722E (de)
RS (1) RS52099B (de)
SI (2) SI1926722T1 (de)
SM (1) SMP200800022B (de)
TN (2) TNSN08089A1 (de)
TW (2) TW200804345A (de)
WO (2) WO2007027950A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070427A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
GB0609378D0 (en) * 2006-05-11 2006-06-21 Novartis Ag Organic compounds
ES2340631T3 (es) 2006-07-21 2010-06-07 Novartis Ag Formulaciones para eteres de bencimidazolil piridilo.
PE20080766A1 (es) * 2006-08-30 2008-06-15 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen
WO2008082730A2 (en) * 2006-09-19 2008-07-10 Novartis Ag Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
US8324389B2 (en) * 2007-03-02 2012-12-04 Novartis Ag Solid forms of a Raf kinase inhibitor
US20100160381A1 (en) * 2007-05-23 2010-06-24 Novartis Ag RAF Inhibitors for the Treatment of Thyroid Cancer
WO2008150015A1 (en) 2007-06-05 2008-12-11 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
JP5270553B2 (ja) 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
WO2009028629A1 (ja) * 2007-08-29 2009-03-05 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
CA2726376A1 (en) * 2008-06-13 2009-12-17 Novartis Ag Substituted benzimidazoles for neurofibromatosis
RU2508110C2 (ru) * 2008-07-11 2014-02-27 Новартис Аг КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek
MX2011004505A (es) * 2008-10-29 2011-05-31 Merck Sharp & Dohme Derivados novedosos de bencimidazol ciclico, utiles como agentes antidiabeticos.
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
JP2011020936A (ja) * 2009-07-14 2011-02-03 Lotte Co Ltd 口臭除去剤
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
WO2011044072A1 (en) 2009-10-05 2011-04-14 Novartis Ag Combination of raf-265 and an activator of ampk for use in the treatment of a proliferative disease
EA201390740A1 (ru) * 2010-11-19 2013-12-30 Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед Способ лечения с использованием ингибитора braf
MX2013009931A (es) 2011-04-18 2013-10-01 Eisai R&D Man Co Ltd Agentes terapeuticos contra tumores.
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
RU2607944C2 (ru) 2011-08-31 2017-01-11 Новартис Аг Синергические композиции ингибиторов pi3k и мек
AU2012335409B2 (en) * 2011-11-09 2017-07-13 Cancer Research Technology Limited 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
CA2855243C (en) 2011-11-11 2020-04-14 Novartis Ag Method of treating a proliferative disease
JP6216325B2 (ja) 2011-11-23 2017-10-18 ノバルティス アーゲー 医薬製剤
US9663503B2 (en) 2012-05-15 2017-05-30 Cancer Research Technology Limited 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
JP2015536964A (ja) 2012-11-08 2015-12-24 ノバルティス アーゲー Ｂ−ｒａｆ阻害剤とヒストン脱アセチル化酵素阻害剤を含む医薬組合せおよび増殖性疾患の治療におけるそれらの使用
CN112641787A (zh) 2013-03-21 2021-04-13 诺华股份有限公司 包含B-Raf抑制剂和第二抑制剂的组合疗法
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
ES2770684T3 (es) 2014-03-14 2020-07-02 Novartis Ag Moléculas de anticuerpos contra LAG-3 y usos de los mismos
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
MX2017004810A (es) 2014-10-14 2017-10-16 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
CN107530415A (zh) 2015-03-10 2018-01-02 艾杜罗生物科技公司 用于活化“干扰素基因刺激物”依赖性信号传导的组合物和方法
US9890187B2 (en) 2015-06-26 2018-02-13 Epos-Iasis Research And Development, Ltd. Prototype systems of theranostic biomarkers for in vivo molecular management of cancer
MX2018000021A (es) 2015-06-30 2018-03-15 Sequessome Tech Holdings Limited Composiciones multifasicas.
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3964528A1 (de) 2015-07-29 2022-03-09 Novartis AG Kombinationstherapien mit antikörpermolekülen gegen lag-3
MX2018005550A (es) 2015-11-03 2019-07-18 Janssen Biotech Inc Anticuerpos que se unen especificamente a tim-3 y sus usos.
CN105481944B (zh) * 2015-12-10 2019-01-08 华南农业大学 一种苯并咪唑衍生物二肽铜配合物及其制备方法和应用
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
US11471538B2 (en) 2017-02-10 2022-10-18 INSERM (Institut National de la Santéet de la Recherche Medicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
WO2018168899A1 (ja) * 2017-03-15 2018-09-20 大日本住友製薬株式会社 ベンズイミダゾール誘導体の製造方法
CN117510405A (zh) * 2017-04-18 2024-02-06 礼来公司 苯基-2-羟基-乙酰氨基-2-甲基-苯基化合物
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
SG11201912473PA (en) 2017-06-22 2020-01-30 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3642240A1 (de) 2017-06-22 2020-04-29 Novartis AG Antikörpermoleküle gegen cd73 und verwendungen davon
WO2019133810A1 (en) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2020097396A1 (en) * 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
SG11202107080VA (en) 2019-01-11 2021-07-29 Naegis Pharmaceuticals Inc Leukotriene synthesis inhibitors
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
US11970494B2 (en) 2021-11-09 2024-04-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894037A (en) 1971-05-24 1975-07-08 Ciba Geigy Corp Certain isothiocyanobenzimidazoles
IL54474A (en) 1977-04-12 1982-04-30 Ciba Geigy Ag Benzimidazole derivatives,their preparation and anthelmintic compositions containing them
US4294926A (en) 1979-06-15 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4319039A (en) 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
JPS5889191A (ja) 1981-11-20 1983-05-27 Sankyo Co Ltd ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法
US4430502A (en) 1982-08-13 1984-02-07 The Upjohn Company Pyridinyl substituted benzimidazoles and quinoxalines
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4911165A (en) 1983-01-12 1990-03-27 Ethicon, Inc. Pliabilized polypropylene surgical filaments
GB8307865D0 (en) 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4782084A (en) 1987-06-29 1988-11-01 Merck & Co., Inc. HMG-COA reductase inhibitors
US4885314A (en) 1987-06-29 1989-12-05 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4820850A (en) 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US5030447A (en) 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5180589A (en) 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US4916239A (en) 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US5290946A (en) 1988-10-13 1994-03-01 Sandoz Ltd. Processes for the synthesis of 3-(substituted indolyl-2-yl)propenaldehydes
US5118853A (en) 1988-10-13 1992-06-02 Sandoz Ltd. Processes for the synthesis of 3-disubstituted aminoacroleins
US4929437A (en) 1989-02-02 1990-05-29 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US5189164A (en) 1989-05-22 1993-02-23 Sandoz Ltd. Processes for the synthesis of syn-(E)-3,5-dihydroxy-7-substituted hept-6-enoic and heptanoic acids and derivatives and intermediates thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JPH06759B2 (ja) 1989-09-22 1994-01-05 ファイザー製薬株式会社 新規なベンゾイミダゾール化合物
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
US5420245A (en) 1990-04-18 1995-05-30 Board Of Regents, The University Of Texas Tetrapeptide-based inhibitors of farnesyl transferase
US5041453A (en) 1990-05-30 1991-08-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene D4
FR2677020B1 (fr) 1991-05-31 1993-08-27 Cird Galderma Composes derives de benzimidazole, leur procede de preparation et leur utilisation dans les domaines therapeutique et cosmetique.
HU9203780D0 (en) 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
CA2111902A1 (en) 1992-12-21 1994-06-22 Jack Beuford Campbell Antitumor compositions and methods of treatment
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
CA2118985A1 (en) 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
EP0763537A3 (de) 1993-05-14 1997-10-22 Genentech Inc Nichtpeptide Farnesyltransferas Inhibitoren
US5602098A (en) 1993-05-18 1997-02-11 University Of Pittsburgh Inhibition of farnesyltransferase
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
GB9602877D0 (en) 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
EP0639573A1 (de) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
US5852046A (en) 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
US5661152A (en) 1993-10-15 1997-08-26 Schering Corporation Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5484799A (en) 1993-12-09 1996-01-16 Abbott Laboratories Antifungal dorrigocin derivatives
US5393790A (en) 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
IL113196A0 (en) 1994-03-31 1995-06-29 Bristol Myers Squibb Co Imidazole derivatives and pharmaceutical compositions containing the same
US5523430A (en) 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
US5510510A (en) 1994-05-10 1996-04-23 Bristol-Meyers Squibb Company Inhibitors of farnesyl protein transferase
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US5571792A (en) 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
CA2155448A1 (en) 1994-08-11 1996-02-12 Katerina Leftheris Inhibitors of farnesyl protein transferase
EP0701907A1 (de) 1994-09-13 1996-03-20 Agfa-Gevaert N.V. Farbstoffdonorelement zur Anwendung in einem thermischen Farbstoffübertragungsverfahren
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5741789A (en) 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US6001866A (en) 1995-10-05 1999-12-14 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US6020343A (en) 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
DE59609305D1 (de) 1995-11-17 2002-07-11 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Herstellung
NZ324834A (en) 1995-12-28 2001-11-30 Fujisawa Pharmaceutical Co Benzimidazole derivatives and their use in reducing blood sugar or as inhibitors of PDE5 activity
GB9602029D0 (en) 1996-02-01 1996-04-03 Fujisawa Pharmaceutical Co New heterocyclic compounds
PT1288206E (pt) 1996-04-12 2008-11-14 Searle Llc Derivados de benzenossulfonamida substituídos como pró-fármacos de inibidores de cox-2
IL127210A0 (en) 1996-05-23 1999-09-22 Applied Research Systems Compounds inhibiting the binding of raf-1 or 13-3-3 proteins to the beta-chain of il-2 pharmaceutical compositions containing them and their use
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
FR2751649B1 (fr) 1996-07-26 1998-08-28 Adir Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6127380A (en) 1997-02-18 2000-10-03 American Home Products Corporation 4-aminoalkoxy-1H-benzoimidazoles
US5932600A (en) 1997-03-14 1999-08-03 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
AU6701598A (en) 1997-03-14 1998-09-29 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
HUP0003934A3 (en) 1997-07-03 2002-01-28 Pfizer A part of diaryl imidazole derivatives, pharmaceutical composit
SI9700186B (sl) * 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
FR2766822B1 (fr) 1997-07-30 2001-02-23 Adir Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
PL344330A1 (en) 1998-05-22 2001-10-22 Smithkline Beecham Corp Novel 2-alkyl substituted imidazole compounds
US6420555B1 (en) 1998-06-16 2002-07-16 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
FR2780973B1 (fr) 1998-07-09 2001-10-05 Hoechst Marion Roussel Inc Procede de preparation du 4-(3-pyridinyl)-1h-imidazole, et les intermediaires mis en oeuvre
DE19834751A1 (de) 1998-08-01 2000-02-03 Boehringer Ingelheim Pharma Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
US6211177B1 (en) 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
KR20010110750A (ko) 1999-04-12 2001-12-13 앤드류 앵뉴 인테그린 길항제로서의 치환된 비사이클릭 헤테로아릴화합물
AU777275B2 (en) 1999-07-02 2004-10-07 Stuart A. Lipton Method of reducing neuronal injury or apoptosis
EP1263753B1 (de) 2000-03-06 2004-05-06 SmithKline Beecham plc Imidazol derivate als raf kinase inhibitoren
US6548517B2 (en) 2000-03-24 2003-04-15 Millennium Pharmaceuticals, Inc. Oxindole inhibitors of factor Xa
AU2001249399A1 (en) 2000-03-24 2001-10-08 Cor Therapeutics, Inc. Isoquinolone inhibitors of factor xa
JP2001322903A (ja) 2000-05-15 2001-11-20 Kumiai Chem Ind Co Ltd 農園芸用殺菌剤組成物
DE60127410T2 (de) * 2000-07-27 2007-12-13 Pharmacia Corp. Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen
AU2001285349A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The University Of Arkansas Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2
JP4734705B2 (ja) 2000-10-31 2011-07-27 三菱化学株式会社 リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池
DE10060292A1 (de) 2000-12-05 2002-06-20 Aventis Pharma Gmbh Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament
MXPA03005298A (es) 2000-12-15 2003-10-06 Vertex Pharma Inhibidores de girasa y usos de los mismos.
TW593278B (en) 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
KR20030072396A (ko) * 2001-02-08 2003-09-13 카로 바이오 아베 갑상선 수용체 리간드
JP2004525140A (ja) * 2001-03-26 2004-08-19 ユニサーチ リミテッド ガンの治療方法及び該治療方法に使用する組成物
BR0208956A (pt) 2001-04-16 2004-07-13 Tanabe Seiyaku Co Abridor de canais de k ativados por cálcio de grande condutância
US6855714B2 (en) 2001-07-06 2005-02-15 Schering Aktiengesellschaft 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
EP1427408A4 (de) 2001-09-17 2005-10-26 Bristol Myers Squibb Co ZYKLISCHE HYDROXAMINSÄUREN ALS HEMMER VON MATRIX-METALLOPROTEINASEN UND/ODER VON TNF-a-KONVERTASE (TACE TNF-a-CONVERTING ENZYM)
WO2003030902A1 (en) 2001-10-09 2003-04-17 Tularik Inc. Imidazole derivates as anti-inflammatory agents
US7039413B2 (en) * 2001-10-24 2006-05-02 Ntt Docomo, Inc. Mobile station transfer control system, cell transfer control method, mobile station, cell transfer control method at mobile station, cell transfer control program, control apparatus, and allocating method of communication resources
TW200300140A (en) 2001-11-14 2003-05-16 Novartis Ag Organic compounds
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
JP4136395B2 (ja) 2002-02-22 2008-08-20 クミアイ化学工業株式会社 農園芸用殺菌剤組成物
DK1499311T3 (da) 2002-03-29 2010-03-08 Novartis Vaccines & Diagnostic Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
US8299108B2 (en) * 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
US7524841B2 (en) 2002-04-25 2009-04-28 Teijin Limited 4,4-disubstituted piperidine derivatives having CCR3 antagonism
TW200400816A (en) * 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
CN101723941A (zh) 2002-08-09 2010-06-09 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体-5调节剂的“1,2,4”二唑
EA200500378A1 (ru) * 2002-09-18 2005-08-25 Пфайзер Продактс Инк. Новые соединения имидазола в качестве ингибиторов трансформирующего фактора роста (tgf)
AU2003271548A1 (en) 2002-10-13 2004-05-04 Neurosearch A/S Use of skca channel blocking drugs for combating parkinson's disease
JP4768265B2 (ja) 2002-10-15 2011-09-07 シンタ ファーマシューティカルズ コーポレーション 新規化合物
US20050054705A1 (en) * 2003-02-04 2005-03-10 Aventis Pharma Deutschland Gmbh N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
EP1608369B1 (de) * 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Verwendung von organischen verbindungen zur immunpotenzierung
PE20050157A1 (es) 2003-05-20 2005-05-17 Novartis Ag Derivados de n-acil nitrogeno heterociclicos como ligandos del receptor activador del proliferador de peroxisoma (ppar)
AU2004251641A1 (en) 2003-05-29 2005-01-06 Synta Pharmaceuticals, Corp Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
CN100447139C (zh) 2003-07-08 2008-12-31 诺瓦提斯公司 苯磺酰氨基化合物和含有这些化合物的药物组合物
US20060205740A1 (en) 2003-08-14 2006-09-14 Reno Michael J Chemical compounds
SI2213661T1 (sl) 2003-09-26 2011-11-30 Exelixis Inc c-Met modulatorji in postopki uporabe
CA2542653A1 (en) 2003-10-16 2005-04-28 Chiron Corporation Substituted benzazoles and use thereof as inhibitors of raf kinase
CA2553433A1 (en) 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer
PE20070427A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
ES2340631T3 (es) * 2006-07-21 2010-06-07 Novartis Ag Formulaciones para eteres de bencimidazolil piridilo.

Also Published As

Publication number Publication date
CA2620472A1 (en) 2007-03-15
JP2013060458A (ja) 2013-04-04
US7732465B2 (en) 2010-06-08
NZ565450A (en) 2011-04-29
PE20070427A1 (es) 2007-04-21
SI1924577T1 (sl) 2011-07-29
BRPI0615309A2 (pt) 2011-05-17
JP2013060457A (ja) 2013-04-04
NI200800060A (es) 2009-03-03
US8592459B2 (en) 2013-11-26
PT1924577E (pt) 2011-07-04
RS52099B (en) 2012-06-30
DE602006021036D1 (de) 2011-05-12
IL189194A0 (en) 2008-06-05
US20070161680A1 (en) 2007-07-12
ECSP088218A (es) 2008-03-26
PT1926722E (pt) 2012-01-11
EP1926722B1 (de) 2011-09-28
HK1117523A1 (en) 2009-01-16
CY1112157T1 (el) 2015-12-09
BRPI0615314A2 (pt) 2011-05-17
ATE503751T1 (de) 2011-04-15
EA200800441A1 (ru) 2008-08-29
HN2008000317A (es) 2011-02-16
AU2006284666B2 (en) 2011-04-28
KR20080039964A (ko) 2008-05-07
US7482367B2 (en) 2009-01-27
MY163886A (en) 2017-11-15
IL189080A (en) 2013-05-30
JP5210867B2 (ja) 2013-06-12
TNSN08088A1 (en) 2009-07-14
IL189080A0 (en) 2008-08-07
AU2006287688B2 (en) 2010-08-19
BRPI0615309B1 (pt) 2021-07-27
SI1926722T1 (sl) 2012-01-31
WO2007030377A1 (en) 2007-03-15
PE20070335A1 (es) 2007-04-21
TW200804346A (en) 2008-01-16
HRP20110312T1 (hr) 2011-08-31
CU23784B7 (es) 2012-02-15
SMAP200800022A (it) 2008-04-02
EP1924577B1 (de) 2011-03-30
US7767820B2 (en) 2010-08-03
JP2009507026A (ja) 2009-02-19
TNSN08089A1 (en) 2009-07-14
TWI387592B (zh) 2013-03-01
NO20081476L (no) 2008-03-26
TW200804345A (en) 2008-01-16
CA2620472C (en) 2013-12-24
ES2374451T3 (es) 2012-02-16
DK1924577T3 (da) 2011-05-16
PL1924577T3 (pl) 2011-09-30
CY1111871T1 (el) 2015-11-04
CU20080027A7 (es) 2010-12-08
EA014230B1 (ru) 2010-10-29
AR057109A1 (es) 2007-11-14
EP1924577A1 (de) 2008-05-28
GEP20105004B (en) 2010-06-10
CR9716A (es) 2008-04-16
CA2619966A1 (en) 2007-03-08
EP1926722A1 (de) 2008-06-04
AU2006287688A1 (en) 2007-03-15
HRP20110939T1 (hr) 2012-01-31
US20100256375A1 (en) 2010-10-07
JP2009507794A (ja) 2009-02-26
AR055622A1 (es) 2007-08-29
SMP200800022B (it) 2008-04-02
JP5210866B2 (ja) 2013-06-12
MA29915B1 (fr) 2008-11-03
DK1926722T3 (da) 2011-12-19
KR20080039965A (ko) 2008-05-07
US20070049622A1 (en) 2007-03-01
IL189194A (en) 2013-09-30
MA29772B1 (fr) 2008-09-01
MY148694A (en) 2013-05-31
US20080287682A1 (en) 2008-11-20
HK1117519A1 (en) 2009-01-16
WO2007027950A1 (en) 2007-03-08
AU2006284666A1 (en) 2007-03-08
PL1926722T3 (pl) 2012-02-29
ECSP088210A (es) 2008-03-26
NZ565451A (en) 2011-05-27
US20100234394A1 (en) 2010-09-16
GT200600394A (es) 2008-03-17
US20090170904A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
ATE526325T1 (de) Substituierte benzimidazole als kinaseinhibitoren
LTC2170860I2 (lt) Benzimidazolo dariniai
ATE512972T1 (de) Pyrrolopyrazole als wirksame kinaseinhibitoren
ATE506358T1 (de) 2-benzylpyridazinonderivate als met-kinasehemmer
ATE549340T1 (de) Spiroindolinon-derivate als mdm2-p53 inhibitoren
ATE479434T1 (de) Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
ATE478064T1 (de) Als pi-3-kinaseinhibitoren verwendete pyrimidinderivate
ATE524467T1 (de) Neuartige aza-heterozyklen als kinase-inhibitoren
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
ATE530545T1 (de) Als kinaseinhibitoren geeignete pyrazolylaminopyridinderivate
BRPI0918846A2 (pt) inibidores de cinase heterocíclica
ATE471940T1 (de) Thienoä3,2-düpyrimidin-derivat geeignet als pi3k inhibitor
ATE540936T1 (de) Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
ATE449091T1 (de) Substituierte triazolderivate als oxytocinantagonisten
ATE541850T1 (de) Pyrroloä2,3-cüpyridinderivate als p38-kinase- hemmende mittel
ATE523505T1 (de) Imidazol-derivate als tafia-inhibitoren
ATE526324T1 (de) Substituierte imidazolverbindungen als ksp- inhibitoren
ATE467623T1 (de) Diazepan-acetamidderivate als selektive 11-hsd1- hemmer
ATE555785T1 (de) Triazolderivate als smo-antagonisten
ATE493403T1 (de) Kinaseinhibitoren
ATE545417T1 (de) Pyrazoloä3,4-büpyridin-derivate als phosphodiesterasehemmer
DK1870409T3 (da) Benzimidazolforbindelser

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1926722

Country of ref document: EP